Abstract：
:Ibrutinib resistance, as a result of coordinated rewiring of signaling networks and enforced tumor microenvironment (TME)-lymphoma interactions, drives unrestrained proliferation and disease progression. To combat resistance mechanisms, we must identify the compensatory resistance pathways and the central modulators of reprogramming events. Targeting the transcriptome and kinome reprogramming of lymphoma cells represents a rational approach to mitigate ibrutinib resistance in B cell malignancies. However, with the apparent heterogeneity and plasticity of tumors shown in therapy response, a one size fits all approach may be unattainable. To this end, a reliable and real-time drug screening platform to tailor effective individualized therapies in patients with B cell malignancies is warranted. Here, we describe the complexity of ibrutinib resistance in B cell lymphomas and the current approaches, including a drug screening assay, which has the potential to further explore the mechanisms of ibrutinib resistance and to design effective individualized combination therapies to overcome resistance and disable aggressive lymphomas (see Outstanding Questions).
journal_name
Trends Cancerjournal_title
Trends in cancerauthors
Shah B,Zhao X,Silva AS,Shain KH,Tao Jdoi
10.1016/j.trecan.2018.01.004subject
Has Abstractpub_date
2018-03-01 00:00:00pages
197-206issue
3eissn
2405-8033issn
2405-8025pii
S2405-8033(18)30019-0journal_volume
4pub_type
杂志文章,评审相关文献
Trends in Cancer文献大全abstract：:The liver is one of the major metabolic organs in the body, susceptible to injury caused by various factors. In response to injury, sophisticated mechanisms are engaged to repair and regenerate the damaged liver, preventing its failure. When the damage is chronic, regeneration goes awry, impairing liver function and c...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.08.005
更新日期：2021-01-01 00:00:00
abstract：:The survival rate of reproductive-age patients with cancer is increasing, reflecting the advent of better and more efficient therapies. Cancer survivors seek the resumption of a normal and healthy life, which often includes starting a family. Unfortunately, many cancer treatments increase the risk of premature ovarian...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2016.03.006
更新日期：2016-05-01 00:00:00
abstract：:Preclinical and clinical data emerging over the past year demonstrate that cancer cells suppress the cytotoxic functions of natural killer cells by a variety of mechanisms. These findings reveal a new arsenal of actionable therapeutic targets to drive clinically relevant immune responses against cancer. ...
journal_title：Trends in cancer
pub_type： 信件
doi：10.1016/j.trecan.2018.12.005
更新日期：2019-03-01 00:00:00
abstract：:The movement toward precision medicine with targeted therapeutics for cancer treatment has been hindered by both innate and acquired resistance. Understanding the molecular wiring and plasticity of oncogenic signaling networks is essential to the development of therapeutic strategies to avoid or overcome resistance. T...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2016.03.008
更新日期：2016-05-01 00:00:00
abstract：:Phosphoinositide 3-kinase (PI3K) generation of PI(3,4,5)P3 from PI(4,5)P2 and the subsequent activation of Akt and its downstream signaling cascades (e.g. mTORC1) dominates the landscape of phosphoinositide signaling axis in cancer research. However, PI(4,5)P2 is breaking its boundary as merely a substrate for PI3K an...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2016.05.009
更新日期：2016-07-01 00:00:00
abstract：:Innate lymphoid cells (ILCs) fulfill important protective and reparative functions, and have thus been implicated in the maintenance of tissue homeostasis. Dysregulation of their activation is associated with several autoimmune and inflammatory diseases. The current literature on the role of ILCs in cancer is limited ...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.03.008
更新日期：2017-05-01 00:00:00
abstract：:TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.01.007
更新日期：2020-02-01 00:00:00
abstract：:Alternative splicing (AS) has many important roles in the pathogenesis of leukemia. Recent papers suggest that one of its key aspects is exclusion of 3'-terminal exons in favor of premature termination using intronic polyadenylation signals. This process generates leukemia suppressor isoforms with truncated C termini ...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.10.005
更新日期：2018-12-01 00:00:00
abstract：:The pace of genomic and immunological breakthroughs in oncology is accelerating, making it likely that large randomized trials will increasingly become outdated before their completion. Traditional clinical research/practice paradigms must adapt to the reality unveiled by genomics, especially the need for customized d...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.12.004
更新日期：2018-02-01 00:00:00
abstract：:Lactate dehydrogenase (LDH) accounts for the fermentative component of aerobic glycolysis, a near ubiquitous metabolic alteration in cancer. Recently, Oshima et al. developed a bioavailable LDH inhibitor that decreases tumor growth in mice and functions synergistically with mitochondrial respiration inhibitors. These ...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.02.012
更新日期：2020-05-01 00:00:00
abstract：:Fusobacterium nucleatum is an oral bacterium associated with colorectal cancer (CRC) proliferation, chemoresistance, inflammation, metastasis, and now DNA damage. While controlling F. nucleatum through antibiotics could reduce cancer severity, this article proposes additional strategies to block Fusobacterium-host int...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.11.006
更新日期：2020-12-09 00:00:00
abstract：:Cancer immunotherapy has recently emerged as a forefront strategy to fight cancer. Key players in antitumor responses are CD8+ cytolytic T lymphocytes (CTLs) that can detect tumor cells that carry antigens, in other words, small peptides bound to surface major histocompatibility complex (MHC) class I molecules. The su...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.07.007
更新日期：2017-10-01 00:00:00
abstract：:Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.04.010
更新日期：2020-08-01 00:00:00
abstract：:Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity ...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.07.002
更新日期：2018-09-01 00:00:00
abstract：:Even though we have known for over 250 years that cancers spread to regional lymph nodes (LNs) and distant organs, the fundamental question of which anatomical routes are taken by tumor cells has remained a mystery. Two recently published papers in Science, by Pereira et al. and Brown et al., directly address this imp...
journal_title：Trends in cancer
pub_type： 评论,杂志文章
doi：10.1016/j.trecan.2018.05.007
更新日期：2018-08-01 00:00:00
abstract：:The Abelson (ABL) tyrosine kinases were identified as drivers of leukemia in mice and humans. Emerging data has shown a role for the ABL family kinases, ABL1 and ABL2, in the progression of several solid tumors. This review will focus on recent reports of the involvement of the ABL kinases in tumor progression using m...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2015.07.004
更新日期：2015-10-01 00:00:00
abstract：:Mitochondria play an essential role in cellular metabolism, generation of reactive oxygen species (ROS), and the initiation of apoptosis. These properties enable mitochondria to be crucial integrators in the pathways of tumorigenesis. An open question is to what extent variation in the mitochondrial genome (mtDNA) con...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.08.004
更新日期：2020-12-01 00:00:00
abstract：:Traditionally, the efficacy of novel cancer therapies has been confirmed in patients failing regular treatment before being tested in early disease. Improved understanding of the mechanisms guiding therapeutic efficacy may challenge this dogma, suggesting novel therapies to move into early evaluation based on biologic...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.11.010
更新日期：2020-12-22 00:00:00
abstract：:Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to devel...
journal_title：Trends in cancer
pub_type： 评论,杂志文章
doi：10.1016/j.trecan.2016.07.002
更新日期：2016-08-01 00:00:00
abstract：:In a recent article, Bisogno et al. reported in a randomized trial that addition of metronomic maintenance therapy (MMT) with vinorelbine plus cyclophosphamide for children with rhabdomyosarcoma resulted in a significant increase in overall and event-free survival. Although the mechanism of action remains to be fully ...
journal_title：Trends in cancer
pub_type： 评论,杂志文章
doi：10.1016/j.trecan.2019.10.004
更新日期：2019-12-01 00:00:00
abstract：:Dynamic changes in the colorectal cancer (CRC) signalome and tumor genetic heterogeneity underlie acquired drug resistance. Improving treatment-related decisions is facilitated by an emerging consensus in the classification of tumor subtypes as well as by real-time monitoring of predictive biomarkers in circulating tu...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.01.003
更新日期：2017-03-01 00:00:00
abstract：:The 'mild' cold stress caused by standard sub-thermoneutral housing temperatures used for laboratory mice in research institutes is sufficient to significantly bias conclusions drawn from murine models of several human diseases. We review the data leading to this conclusion, discuss the implications for research and s...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2016.03.005
更新日期：2016-04-01 00:00:00
abstract：:The rapidly evolving field of cancer immunotherapy recently saw the approval of several new therapeutic antibodies. Several cell therapies, for example, chimeric antigen receptor-expressing T cells (CAR-T), are currently in clinical trials for a variety of cancers and other diseases. However, approaches to monitor cha...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.03.009
更新日期：2018-05-01 00:00:00
abstract：:Neutrophil extracellular traps (NETs) have emerged as significant contributors to cancer-associated pathologies such as metastasis, thrombosis, and organ dysfunction in preclinical models. We review recent discoveries of the involvement of NETs in human cancers and suggest tumor-induced NET formation as an interesting...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2016.10.012
更新日期：2016-11-01 00:00:00
abstract：:GLI-similar 1-3 (GLIS1-3), a subfamily of Krüppel-like zinc finger transcription factors, function as key regulators of several biological processes important to oncogenesis, including control of cell proliferation, differentiation, self-renewal, and epithelial-mesenchymal transition. This review provides a short over...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2019.07.005
更新日期：2019-09-01 00:00:00
abstract：:Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consid...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.02.014
更新日期：2020-06-01 00:00:00
abstract：:The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular inter-tumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic and epigenomic profiling. Distinct mole...
journal_title：Trends in cancer
pub_type： 评论,杂志文章
doi：10.1016/j.trecan.2016.04.003
更新日期：2016-05-01 00:00:00
abstract：:Immuno-oncology has gained momentum thanks to the success of strategies aimed at enhancing immune-mediated antitumor response. The field of immunotherapeutic transport oncophysics investigates the physical processes that drive cancer immunotherapies. This review discusses three main aspects that determine the outcome ...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2019.11.008
更新日期：2020-01-01 00:00:00
abstract：:In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this se...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.05.014
更新日期：2020-09-01 00:00:00
abstract：:Although immunotherapy has proved to be effective in a variety of cancer subtypes, the role of immune checkpoint inhibition in the treatment of prostate cancer remains unclear. Here we review results from the latest clinical trials and discuss data suggesting that certain genetic mutations may confer increased sensiti...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.01.003
更新日期：2020-03-01 00:00:00
